Loading...
Derniers manuscrits de l'équipe
-
Paolo Antonio Ascierto, Evan Lipson, Reinhard Dummer, James Larkin, Georgina Long, et al.. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. Journal of Clinical Oncology, 2023, Online ahead of print. ⟨10.1200/JCO.22.02072⟩. ⟨inserm-03996644⟩
-
Arnaud de La Fouchardiere, Franck Tirode, Christine Castillo, Adrien Buisson, Felix Boivin, et al.. Attempting to Solve the Pigmented Epithelioid Melanocytoma (PEM) Conundrum PRKAR1A Inactivation Can Occur in Different Genetic Backgrounds (Common, Blue, and Spitz Subgroups) With Variation in Their Clinicopathologic Characteristics. American Journal of Surgical Pathology, 2022, 46 (8), pp.1106-1115. ⟨10.1097/PAS.0000000000001888⟩. ⟨hal-03780357⟩
-
Nicolas Macagno, Daniel Pissaloux, Arnaud de La Fouchardiere, Marie Karanian, Sylvie Lantuejoul, et al.. Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosis. GENES CHROMOSOMES & CANCER, 2022, 61 (6, SI), pp.382-393. ⟨10.1002/gcc.23026⟩. ⟨hal-03780373⟩
Chiffres clés
28
Publications avec texte intégral